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OBJECTIVES This study sought to test whether insulin improves exercise ventilatory efficiency (VE/VCO2
slope) and oxygen uptake at peak exercise (peak VO2) in patients with type 2 diabetes–heart
failure (HF) comorbidity.
BACKGROUND In type 2 diabetes–HF comorbidity, depression of alveolar–capillary diffusion (DLCO)
correlates with deterioration of exercise VE/VCO2 slope and peak VO2. Insulin potentiates
DLCO in these patients.
METHODS Exercise ventilatory efficiency and peak VO2 (cycle ergometry ramp protocol), as well as
DLCO at rest and its subdivisions (membrane conductance [DM] and pulmonary capillary
blood volume [VC]) were assessed in 18 patients with type 2 diabetes–HF comorbidity at
baseline and after 50 ml of saline  regular insulin (10 IU), or saline, was infused on
consecutive days, according to a random crossover design. Glycemia was kept at pre-insulin
level for the experiment duration.
RESULTS Baseline DLCO, DM, peak VO2, and VE/VCO2 slope were compromised in these patients.
At measurements performed in the 60 min after infusions, compared with at baseline, saline
was ineffective, whereas insulin augmented peak VO2 (13.5%) and lowered VE/VCO2
slope (18%), and also increased time to anaerobic threshold (29.4%), maximal O2 pulse
(12.3%), aerobic efficiency (21.2%), DLCO (12.5%), and DM (21.6%), despite a
reduction in VC (16.3%); insulin did not vary cardiac index and ejection fraction at rest.
Changes in peak VO2 and VE/VCO2 slope (r  0.67, p  0.002; r  0.73, p  0.001,
respectively) correlated with those in DLCO. These responses were unrelated to glycohemo-
globin and baseline fasting blood sugar. They were persistent at 6 h after insulin infusion, and
were undetectable at 24 h.
CONCLUSIONS In diabetes–HF comorbidity, insulin causes a prolonged improvement in physical perfor-
mance through activation of multiple factors, among which facilitation of gas conductance
seems to be predominant. (J Am Coll Cardiol 2003;42:1044–50) © 2003 by the American
College of Cardiology Foundation
Diabetes mellitus, as a comorbid disease, frequently con-
founds heart failure (HF) and adds significantly to its overall
morbidity (1–3). Poor glycemic control is associated with an
increased risk of HF in type 2 diabetes (4,5); blood glucose
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control substantially reduces the risk of vascular complica-
tions (4) and improves endothelial function (6). At the lung
level, the alveolar–capillary membrane becomes a target
structure of the coexisting diseases; left ventricular dysfunc-
tion causes a hydrostatic stress on the membrane (7), and
diabetes alters the alveolar and pulmonary capillary basal
laminae (8), resulting in a synergistic depression of the
membrane conductance and gas exchange (9). This alter-
ation correlates with a joint adverse influence of these
diseases on exercise ventilatory efficiency and peak exercise
oxygen uptake (peak VO2) (9). In the setting of comorbid-
ity, insulin may be beneficial. The hormone, in fact, reduces
mortality in diabetes after acute myocardial infarction (10),
improves hemodynamics in HF without diabetes (11),
attenuates impedance to alveolar–capillary interface gas
transfer in patients with diabetes (12) and even more in case
of comorbidity (13). There is no report concerning an
influence of insulin on exercise ventilatory efficiency and
oxygen uptake (VO2). This does not seem to be an unreal-
istic possibility if one considers the relationship between
these variables and gas exchange, and the effect insulin has
on pulmonary gas transfer in patients with diabetes in
addition to HF. The aims of this study were as follows:
1. to assess whether in cases with coexisting diseases,
insulin ameliorates exercise performance and
2. to explore whether improvement in alveolar–capillary
membrane conductance may have a role in these effects.
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METHODS
Study population. This study includes 18 patients who
were referred for evaluation of chronic HF. All gave written
consent to the procedures, and the research was approved by
the ethical review committee of the hospital. All had type 2
diabetes mellitus and none had participated in previous
studies in our laboratory. Carboxyhemoglobin concentra-
tion was2%, a value compatible with that of non-smoking
urban dwellers. Glycosylated hemoglobin levels averaged
6.2  0.3% on therapy (the normal range in our laboratory
is 4% to 5.5%). Hyperglycemia was controlled by diet alone
(n  2), or plus sulfonylurea (n  9) or metformin (n  7).
These were consecutive patients who were enrolled if they
had chronic stable New York Heart Association functional
class II to III HF from previous myocardial infarction (n 
11) or idiopathic cardiomyopathy (n  7) (cardiac enlarge-
ment without a specific cause for left ventricular impair-
ment); if ejection fraction was 35%; and if they were able
to complete a maximal cardiopulmonary exercise test. Pul-
monary function was not a selection measure. Patients were
excluded if they had hypertension, pulmonary disease, or
had smoked 10 cigarettes per day during one of the past
five years (all had abstained from tobacco products for at
least nine months before enrollment, and four patients had
never smoked); if exercise was limited by symptoms other
than dyspnea or fatigue and they developed electrocardio-
graphic changes of myocardial ischemia on effort; if they
had clinically evident distal symmetrical neuropathy, auto-
nomic insufficiency, or renal impairment, all of which can
alter exercise performance (9). Patients who received beta-
adrenergic blocking agents or who, at Doppler velocimetry,
presented with mitral regurgitation exceeding grade 2 on a
scale of 0 to 5 also were not included. The antifailure
treatments prescribed by the referring physicians included
digoxin, loop diuretics, and angiotensin-converting enzyme
inhibitors in all, nitrates in two, and aspirin in five.
Pulmonary function. Diffusion of carbon monoxide
(DLCO) was assessed with Sensor Medics 2200 Pulmonary
Function Test System (Anaheim, California). The mea-
surement was determined twice with a standard, single-
breath technique. Reference equations were used when
values were expressed as percentage of normal predicted
(14). The single-breath alveolar volume (VA) was derived
by methane dilution. The subdivisions of DLCO, i.e., the
alveolar–capillary membrane diffusion capacity (DM) and
the capillary pulmonary blood volume available for gas
exchange (VC), were determined, according to the classic
Roughton and Forster method (15), as previously reported
(16). Lung diffusing capacity for carbon monoxide and its
subcomponents were expressed in absolute values, as well as
per unit of VA (DLCO/VA, DM/VA, VC/VA). The pro-
portion of total pulmonary diffusive resistance ascribable to
the alveolar–capillary interface was calculated (DLCO/DM).
Exercise. Cycle ergometry exercise was performed in an
upright position, using an individualized ramp protocol
according to the preliminary assessment of the patient’s
functional capacity, to ensure a test duration of 10 min
and to avoid premature fatigue. Breath-by-breath gas ex-
change analysis was performed at rest and throughout
exercise using a Sensor Medics Vmax 29C system (Yorba
Linda, California). Respiratory gas was sampled continu-
ously from a mouthpiece, and minute ventilation (VE),
VO2, carbon dioxide output (VCO2), and respiratory ex-
change ratio (RER) were calculated. The V-slope analysis
was used to calculate the anaerobic threshold (AT). Venti-
latory efficiency was assessed by calculating the slope of the
increase in ventilation with respect to CO2 production
(VE/VCO2 slope). Oxygen consumption at the AT, and the
rate at which VO2 increased per work rate (VO2/WR),
as an indicator of aerobic efficiency, were also measured.
The rate at which VO2 increased per work rate was calculated
for the progressively increasing exercise period beginning 1 min
after WR started to increase. The delay of 1 min after the start
of increase in WR was used to take into account the time
constant for VO2 to respond to the increasing WR (around
35 s for normal subjects) (17). Peak VO2 was determined by
the highest VO2 achieved during exercise. Age-, gender-, and
weight-adjusted predicted VO2 values were also determined.
The maximal O2 pulse was measured by dividing the highest
VO2 by the maximal heart rate.
Echocardiography. Two-dimensional and Doppler echo-
cardiography were performed by standard methods. Pulmo-
nary artery systolic pressure, left ventricular end-systolic and
end-diastolic chamber dimensions and left ventricular vol-
ume, by the area–length method (to measure ejection
fraction), were quantitated by standard techniques. Stroke
volume was calculated as the velocity time integral of the
systolic velocity spectrum in the outflow tract multiplied by
the subaortic area of the outflow tract.
Protocol. All patients were admitted to the hospital, were
maintained on their current drug treatment, and were fed a
diet containing 160 g carbohydrate/day. Routine laboratory
Abbreviations and Acronyms
DLCO  lung diffusing capacity for carbon
monoxide
DM  alveolar–capillary membrane diffusion
capacity
HF  heart failure
peak VO2  oxygen consumption at peak exercise
VA  alveolar volume
VC  pulmonary capillary blood volume
available for gas exchange
VCO2  carbon dioxide production
VE/VCO2 slope  slope of the increase in ventilation
with respect to carbon dioxide
production
VO2  oxygen uptake
VO2 AT  oxygen consumption at the anaerobic
threshold
VO2/WR  rate of oxygen consumption increase
per work rate
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work and cardiac evaluation were performed on the day of
admission. On the second day, subjects were familiarized
with exercise testing and performed a graded maximal
exercise test to determine peak VO2. On the third day, they
underwent an evaluation of pulmonary function including
exchange capacity, pulmonary artery systolic pressure, ejec-
tion fraction and cardiac output, as well as an individualized
exercise ramp test; these measurements were taken as the
reference baseline parameters. On the following day, infu-
sion studies were performed after a 12-h overnight fast and
withdrawal of the morning oral hypoglycemic drugs, in a
sitting position, in a quiet room. A catheter needle was
inserted into an antecubital vein of each arm for infusions
and blood drawing, respectively. After 30 min rest, 50 ml
normal saline were infused intravenously, at a rate of 1.0
ml/min, that either contained or did not contain 10 IU of
regular insulin (Humulin; Eli Lilly and Co., Indianapolis,
Indiana). Glycemia was determined before infusion, at
10-min intervals during infusion, and 60 min after comple-
tion of the same. Blood glucose was kept at the baseline
level during the experiment by administering, when neces-
sary, intravenous 20% dextrose solution according to glyce-
mia; the supplemented volume ranged between 20 and 80
ml. Serum potassium levels remained above 3.8 mEq/l in
each patient during all phases of the study.
Those incharged for exercise and those incharged for
infusions were not admitted at the same time to the room
where experiments were performed and were not allowed to
communicate with each other. By this method the main
outcome variables of the study were investigated in a blind
fashion.
The short-term effects of insulin were investigated in all
participants by re-evaluating lung and cardiac function at
rest and exercise testing in the 60 min after infusion. On the
following morning the same procedures were repeated while
patients were switched to insulin or to inactive solution
according to a random design. To determine the duration of
the insulin effects, all measurements were repeated after a
two-day washout period and were taken as the reference
baseline parameters for the second part of the study, in
which insulin and saline were given again according to the
protocol already described, the only difference being a 6-h
interval before the post-infusion evaluations.
Statistical analysis. Values are expressed as mean  SD.
Multiple comparison ANOVA test was used to compare the
responses to saline and to insulin infusions. The two sets of
baseline reference measurements performed in the two parts
of the study were analyzed using the paired samples Stu-
dent’s t test.
The relationship between resting lung function tests and
exercise parameters was assessed using the Pearson coeffi-
cient of correlation. A p value of  0.05 was considered to
be statistically significant. Statistical analyses were per-
formed by means of Stata 7.0 package (Stata Corp., College
Station, Texas).
RESULTS
Table 1 and Table 2 show that in the baseline fasting
glycemia and glycohemoglobin were moderately elevated,
ejection fraction and cardiac index were depressed, systolic
pulmonary pressure was raised, forced expiratory volume in
1 s and vital capacity were not consistent with airway
obstruction, DLCO and DLCO/VA were reduced to 69.2 
5.8% and to 63.8 10.9%, respectively, of predicted normal
values (14) (below levels reported in the literature for HF
alone) (18). The proportion of diffusive resistance ascribable
to alveolar–capillary interface averaged 74.6  7.4%. Peak
VO2 was compromised, and the VE/VCO2 slope, in all
patients but one, exceeded the value of 30, which is the
upper normal limit (19). The VO2/WR, which reflects
the oxygen utilized per unit increase in work rate and is an
index of aerobic efficiency, was below the lower normal limit
of 8.6 (20) and averaged 7.8  2.1 mlW1min1.
At measurements accomplished in the 60 min after insulin
infusion (Table 2) compared with those taken at baseline,
systemic hemodynamics were steady, pulmonary systolic pres-
sure was reduced. There was also a significant increase in
carbon monoxide diffusion (DLCO, 12.5%) and its mem-
brane component (DM, 21.6%). These changes, when ex-
pressed per unit of VA, were: DLCO/VA, 18.9%; DM/VA,
26.5%. Insulin also reduced the pulmonary capillary blood
volume (VC,16.3%) and (DLCO/DM,9%). The individual
values reported in Figure 1 show that in the great majority of
patients there was an improvement of DLCO, DM, peak VO2,
and a decrease of VE/VCO2 slope. Compared with baseline
reference measurements, insulin augmented peak VO2 by 2.2
mlkg1min1 (13.5%) and reduced VE/VCO2 slope by
18%. There was also an increase in time to anaerobic threshold
(29.4%), O2 pulse (12.3%), and VO2/WR (21.2%).
Saline alone, compared with baseline measurements, did not
have any effect on the pulmonary gas exchange and exercise
capacity.
Variations in peak VO2 and VE/VCO2 slope from
baseline with insulin correlated significantly with those in
Table 1. Baseline Characteristics of the Study Patients
Number 18
Gender, M/F 12/6
Age, yrs 60.7  6.4
Weight, kg 73.9  7.6
Body mass index, kg/m2 26  1
Etiology of HF, IHD/DCM 10/6
Digoxin, mg/day 0.23  0.02
Furosemide, mg/day 73  7.1
Mitral regurgitation, subjective scale (0–5) 1.2  0.6
Vital capacity, % predicted 71.7  12
Forced expiratory volume in 1 s, % predicted 82.6  11
Fasting glucose, mg/dl 135  14
Cholesterol, mg/dl 222  18
Triglyceride, mg/dl 199  13
Glycohemoglobin, % 6.2  0.3
Duration of diabetes, yrs 9.2  3
DCM dilated cardiomyopathy; HF heart failure; IHD ischemic heart disease.
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DLCO (Fig. 2, r  0.67 p  0.002, and r  0.73, p 
0.001, respectively). We did not find a correlation of age,
time from diabetes diagnosis, glycohemoglobin, and base-
line fasting blood sugar with DLCO or DM.
All changes were not present 24 h later at measurements
performed in patients who were given saline alone as second
test drug. On the contrary, in the second part of the study,
measurements performed at 6 h after infusion showed that the
improvement from baseline (reference values were not signif-
icantly different from those in the first part of the study) in
DLCO, DM, peak VO2, VE/VCO2 slope, and VO2/WR
was persistent and statistically significant (Table 3).
DISCUSSION
The main information provided by this study is that in
patients with coexistence of type 2 diabetes and HF, insulin
was associated with amelioration in exercise ventilatory
efficiency and VO2. Insulin also produced an improvement
in the alveolar–capillary gas conductance that was signifi-
cantly related with the decreased VE/VCO2 slope and the
increased peak VO2. These effects were not due to variations
in glycemia.
Changes in DLCO versus changes in VE/VCO2 slope.
Elevation of the hydrostatic forces and upregulation of
sodium transport across the capillary endothelium by HF
(16,21), and disturbances in microvascular permeability by
diabetes (8,22), may concur to facilitate alveolar interstitial
fluid accumulation and impedance to gas exchange. Insulin
has the potential to reduce interstitial fluid accumulation
and shorten the gas diffusion path in patients with diabetes
or comorbidity, through an increase in inotropy (23) and a
decrease of impedance to left ventricular ejection (23)
(resulting in a reduction of the pulmonary hydrostatic
forces), and by an enhancement of the defective release in
diabetes of endothelium-derived nitric oxide and vasodilat-
ing prostaglandins (4,24–26). These substances are involved
in the modulation of the pulmonary vascular tone and
permeability and can reduce the tissue component of resis-
tance to the oxygen transfer from the alveolus to its uptake
by hemoglobin. How much of the benefit on gas exchange
is due to a pulmonary vasodilating effect of insulin, which
decreases pulmonary artery pressure, cannot be estimated.
Previous observations, however, do not support a major role
for changes in pulmonary hemodynamics. In fact, insulin is
Table 2. Mean Plasma Glucose Concentration, Circulatory and Respiratory Values at Rest, and
Exercise Parameters, in the Baseline and 60 Min After Infusion of Saline Plus Regular Insulin
(10 IU) or of Saline Alone
Baseline Insulin Saline
Plasma glucose, mg/dl 135  14 133  12 137  9
Heart rate, beats/min 76  2 79  2 74  2
Systemic arterial pressure, mm Hg
Systolic 125.4  12 123.9  11 126.1  10
Diastolic 76.5  5.5 75.3  5.8 78.3  5.1
Cardiac index, lmin1m21 2.59  1.7 2.60  2.0 2.65  1.8
LV ejection fraction, % 28.8  0.4 29.2  0.3 29.5  0.5
Pulmonary artery systolic pressure, mm Hg‡ 31.3  3.4 26.7  2.9*† 32.6  3.8
DLCO, mlmin
1mm Hg1 18.7  3.6 21.05  3.9*† 18.3  4.0
DLCO, % predicted 69.2  5.8 77.9  5.6 67.7  5.7
DM, mlmin
1mm Hg1 25.4  7.2 30.9  6.2*† 25.7  6.6
VC, ml 98.5  17.1 80.5  20.6*† 101  16.3
DLCO/VA, mlmin
1mm Hg1l1 3.7  0.7 4.4  0.6*† 3.8  0.8
DLCO/VA, % predicted 63.8  10.9 75.9  10.2*† 65.5  10.7
DM/VA, mlmin
1mm Hg1l1 4.9  1.3 6.2  1.8*† 4.6  1.5
VC/VA, ml1
1 23.8  2.5 22.1  2.1*† 24.3  2.3
DLCO/DM, % predicted 74.6  7.4 68.1  8.9*† 73.0  9.1
Peak heart rate, beats/min 130  10 128  9 129  10
Peak systolic blood pressure, mm Hg 160  18 160  20 158  19
Peak workload, W 90  30 102  28*† 92  30
Peak VO2, mlkg
1min1 16.3  2.7 18.5  3.2*† 15.9  4.8
Peak VO2, % predicted 75.5  3.1 86.1  3.8 73.6  2.9
Workload at AT, W 60  25 70  30 62  30
AT, min 3.4  0.7 4.3  0.6*† 3.2  0.5
VO2 AT, mlkg
1min1 11.6  3.1 13.8  3.8*† 11.4  4.0
O2 pulse, ml/beat 9.9  2.3 11.3  3.1 10.4  2.7
Peak VE, l/min 60  20 63  18 61  19
Peak RER 1.02  0.2 1.07  0.3 1.04  0.4
VE/VCO2 slope 39  4.6 32  4.2*† 38.4  3.8
VO2/WR, mlW
1min1 7.8  2.1 9.9  1.9*† 8.0  1.7
*p  0.01 vs. baseline; †p  0.01 vs. saline; ‡means of 14 patients.
AT  anaerobic threshold; DLCO  carbon monoxide diffusion; DM  alveolar-capillary membrane diffusing capacity;
LV  left ventricle; RER  respiratory exchange ratio; VA  alveolar volume; VC  pulmonary capillary blood volume;
VCO2  carbon dioxide production; VE  ventilation; VO2  oxygen consumption; WR  work rate.
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not significantly effective on the impedance to gas transfer in
HF patients without diabetes (13); hydralazine and isosor-
bide dinitrate, which are quite effective in reducing pulmo-
nary artery pressure and arteriolar resistance in HF patients,
fail to improve DLCO (27). The possibilities should also be
considered that saline, the vehicle used for insulin infusion,
Figure 1. Individual responses to insulin of the pulmonary gas exchange and exercise capacities. Filled circles are the means  SD. *p  0.01 vs. baseline.
DLCO  lung diffusing capacity for carbon monoxide; DM  diffusing capacity of the alveolar-capillary membrane; peak VO2  oxygen consumption at
peak exercise; Vc  pulmonary capillary volume available for gas exchange; VE/VCO2 slope  slope of the increase in ventilation with respect to carbon
dioxide production; VO2AT  oxygen consumption at the anaerobic threshold.
Figure 2. Individual changes in carbon monoxide diffusion (DLCO) vs. changes in peak exercise oxygen uptake (peak VO2) and in the slope of increase
in ventilation with respect to carbon dioxide production (VE/VCO2 slope), after insulin infusion.
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may have depressed the lung diffusing capacity in HF
patients (28), or that aspirin counteracted the facilitating
effect that angiotensin-converting enzyme inhibitors exert
on alveolar–capillary membrane conductance (27). These
effects, however, would tend, if anything, to attenuate the
response to insulin; therefore, they do not detract from our
results.
The origin of a steep slope of ventilation to CO2
production on exercise may be multifactorial: increase of the
ventilation required to overcome a large dead space, aug-
mented central drive to ventilation originating from
J-receptor activation in consequence of the distended inter-
stitial space, bicarbonate buffering of accumulating lactic
acid, reduced perfusion of ventilating lung, abnormal central
or reflex chemosensitivity, overactive ergoreceptors, abnor-
mal autonomic and baroreceptor control of the circulation
(29,30). This study does not define which factor may be the
target of the joint influence of diabetes and HF and whether
insulin exerts a protective activity. However, the ameliora-
tion in alveolar–capillary conductance, as possibly mediated
by reduction of lung interstitial space overdistention, and its
correlation with the improvement in VE/VCO2 slope are
indicative of an involvement of the membrane effects of
insulin in the ameliorated ventilatory efficiency. Likewise,
the increase in time to AT (delayed reliance on anaerobic
pathways for energy production) and in VO2/WR (po-
tentiated aerobic efficiency), are consistent with an interfer-
ence of insulin with several mechanisms underlying the
enhancement of VE/VCO2 slope in patients with comor-
bidity.
Changes in DLCO versus changes in peak VO2. Im-
provement in exercising skeletal muscle perfusion (11,23)
and glucose uptake (given the marked change in aerobic
efficiency), and in cardiac output response to exercise
(achievement of a higher O2 pulse), may well explain the
benefits of insulin on VO2. Insulin has a physiological role
to vasodilate skeletal muscle vasculature, and this action is
impaired in states of insulin resistance, such as type 2
diabetes and chronic HF (23). The observed increase in
VO2/WR is consistent with an improvement in exercis-
ing muscle perfusion and/or an increase in cardiac output
(increase in O2 pulse). Using a similar protocol, in a
comparable group of HF patients without diabetes, Parson-
age et al. (11) have seen a beneficial central (increase in
cardiac output) and peripheral (augmented forearm blood
flow) effect of insulin. The extent of skeletal muscle perfu-
sion can be an important determinant of insulin-mediated
glucose uptake (31). In our population, baseline peak RER
averaged 1.02 and increased to 1.07 and 1.04, 60 min and
6 h after insulin, respectively. This is in favor of increased
cellular glucose availability and improved substrate
utilization.
Although the correlation between changes in DLCO and
those in peak VO2 may simply reflect association, a few
compelling comments are in order. In HF, exercise raises
the capillary pulmonary pressure and the fluid–flux transi-
tion (factors that underlie (7) alveolar–capillary membrane
stress); the physiological increase in gas exchange during
exercise is restrained at the level of the membrane (impeded
increase in conductance because of excessive fluid filtration
to the alveolar interstitium), and capillary recruitment for
gas exchange is inadequate. Coexistence of diabetic distur-
bances in the microvessel permeability might enhance the
excessive fluid passage in the interstitial space, which re-
strains gas conductance, and makes the capillary recruitment
during exercise even more inadequate. In this setting,
hyperventilation might help maintain oxygen alveolar ten-
sion at normal levels, but could precipitate premature
Table 3. Circulatory and Respiratory Values at Rest and Exercise Parameters in the Baseline and
6 h After Regular Insulin (10 IU) or Saline Infusions
Baseline Insulin Saline
Plasma glucose, mg/dl 146  11 141  8 142  10
Cardiac index, lmin1m21 2.41  1.9 2.59  2.0 2.52  1.9
LV ejection fraction, % 27.9  0.6 27.1  0.5 28.3  0.7
Pulmonary artery systolic pressure, mm Hg 33.3  4.1 26.8  3.2†‡ 35.1  4.5
DLCO, mlmin
1mm Hg1 17.7  3.2 20.9  3.3†‡ 18.1  4.1
DM, mlmin
1mm Hg1 24.5  6.4 29.2  4.6*§ 24.1  5.9
Peak heart rate, beats/min 131  11 130  11 130  10
Peak systolic blood pressure, mm Hg 158  20 159  18 160  20
Peak workload, W 95  25 104  24†‡ 96  30
Peak VO2, mlkg
1min1 15.7  1.9 18.3  2.3†‡ 15.3  3.2
Peak VO2, % predicted 76.6  3.8 85.8  4.2†‡ 77.2  3.1
Workload at AT, W 58  25 69  25†‡ 60  25
AT, min 3.1  0.6 3.6  0.8 3.2  0.5
VO2 AT, mlkg
1min1 11.2  2.8 12.8  3.4 11.5  3.3
O2 pulse, ml/beat 9.2  1.8 9.8  2.3 9.0  2.4
Peak VE, l/min 61  20 62  22 60  24
Peak RER 1.02  0.3 1.04  0.3 1.01  0.3
VE/VCO2, slope 40.3  4.3 34.1  4.1*§ 39.2  3.8
VO2/WR, mlW
1min1 7.4  2.6 9.2  2.2†‡ 7.0  1.8
*p  0.01 vs baseline; †p  0.05 vs. baseline; ‡p  0.05 vs. saline; §p  0.01 vs. saline; means of 14 patients.
Abbreviations as in Table 2.
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exhaustion of the ventilation reserve (32) and early inter-
ruption of exercise. Consistent with this interpretation are
the correlations reported in HF patients between peak VO2
and lung diffusion (31,32), as well as the acute decrease of
peak VO2 and increase of VE/VCO2 slope after an acute
depression of DM (33).
These considerations substantiate the possibility that a
compromised gas exchange efficiency participates in depressing
both peak VO2 and ventilatory efficiency in diabetes–HF
comorbidity, and that it represents a background for the
benefits of insulin on these variables. It is significant that the
two patients in whom peak VO2 reduced with insulin also
showed worsening of ventilatory efficiency and membrane
conductance (Fig. 1). Findings at 6 h suggest that the insulin-
mediated changes are prolonged. This is a significant point in
relation to a hypothetical therapeutic applicability.
Study limitations. The existence of a dose-related effect
has not been defined. It is also unknown whether insulin
resistance in type 2 diabetes (1) and HF (11) was at work in
patients with comorbidity, and influenced the responses to
the exogenous infusion of the hormone, and whether ACE
inhibition, which exerts several protective influences in
diabetes (3), can add to insulin’s effects.
Conclusions. Insulin in type 2 diabetes–HF comorbidity
improves exercise performance. Several factors are likely
involved in these effects; a facilitation of gas conductance at
the lung level seems to play a significant role.
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